Incidence of Tumour Progression and Pseudoprogression in High-Grade Gliomas: a Systematic Review and Meta-Analysis

被引:104
|
作者
Abbasi, Abdul W. [1 ]
Westerlaan, Henriette E. [1 ]
Holtman, Gea A. [3 ]
Aden, Kamal M. [1 ]
van Laar, Peter Jan [1 ,2 ]
van der Hoorn, Anouk [1 ,2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol, Hanzepl 1,30-001, NL-9700 RB Groningen, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Ctr Med Imaging North East Netherlands, Groningen, Netherlands
[3] Univ Groningen, Univ Med Ctr Groningen, Dept Gen Practice, Groningen, Netherlands
关键词
Treatment response assessment; Meta-analysis; Pseudoprogression; Incidence; High-grade gliomas; DIFFERENTIATING RADIATION NECROSIS; RECURRENT GLIOBLASTOMA-MULTIFORME; MAGNETIC-RESONANCE SPECTROSCOPY; APPARENT DIFFUSION-COEFFICIENT; CENTRAL-NERVOUS-SYSTEM; CEREBRAL BLOOD-VOLUME; TRUE PROGRESSION; MALIGNANT GLIOMA; PSEUDO-PROGRESSION; BRAIN-TUMOR;
D O I
10.1007/s00062-017-0584-x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background High-grade gliomas are the most common primary brain tumours. Pseudoprogression describes the false appearance of radiation-induced progression on MRI. A distinction should be made from true tumour progression to correctly plan treatment. However, there is wide variation of reported pseudoprogression. We thus aimed to establish the incidence of pseudoprogression and tumour progression in high-grade glioma patients with a systematic review and meta-analysis. Methods We searched PubMed, Embase and Web of Science on the incidence of pseudoprogression and tumour progression in adult high-grade glioma patients from 2005, the latest on 8 October 2014. Histology or imaging follow-up was used as reference standard. Extracted data included number of patients with worsening of imaging findings on T1 postcontrast or T2/FLAIR, pseudoprogression and tumour progression. Study quality was assessed. Heterogeneity was tested with I (2) . Pooling of the results was done with random models using Metaprop in STATA (StataCorp. Stata Statistical Software. College Station, TX: StataCorp LP). Results We identified 73 studies. MRI progression occurred in 2603 patients. Of these, 36% (95% confidence interval [CI] 33-40%) demonstrated pseudoprogression, 60% (95%CI 56-64%) tumour progression and unknown outcome was present in the remaining 4% of the patients (range 1-37%). Conclusion This meta-analysis demonstrated for the first time a notably high pooled incidence of pseudoprogression in patients with a form of progression across the available literature. This highlighted the full extent of the problem of the currently conventional MRI-based Response Assessment in Neuro-Oncology (RANO) criteria for treatment evaluation in high-grade gliomas. This underscores the need for more accurate treatment evaluation using advanced imaging to improve diagnostic accuracy and therapeutic approach.
引用
收藏
页码:401 / 411
页数:11
相关论文
共 50 条
  • [31] Prognostic utility of gene therapy with herpes simplex virus thymidine kinase for patients with high-grade malignant gliomas: a systematic review and meta analysis
    Zhao, Fei
    Tian, Jinhui
    An, Lifeng
    Yang, Kehu
    JOURNAL OF NEURO-ONCOLOGY, 2014, 118 (02) : 239 - 246
  • [32] Evaluation of perfusion MRI value for tumor progression assessment after glioma radiotherapy A systematic review and meta-analysis
    Wang, Longlong
    Wei, Lizhou
    Wang, Jingjian
    Li, Na
    Gao, Yanzhong
    Ma, Hongge
    Qu, Xinran
    Zhang, Ming
    MEDICINE, 2020, 99 (52)
  • [33] Risk Factors for High-Grade Meningioma in Brain and Spine: Systematic Review and Meta-analysis
    Shin, Hong Kyung
    Park, Jin Hoon
    Cho, Young Hyun
    Kim, Young-Hoon
    Hong, Seok Ho
    Kim, Jeong Hoon
    Roh, Sung Woo
    Jeon, Sang Ryong
    WORLD NEUROSURGERY, 2021, 151 : E718 - E730
  • [34] Based on arterial spin labeling helps to differentiate high-grade gliomas from brain solitary metastasis A systematic review and meta-analysis
    Fu, Min
    Han, Fang
    Feng, Changchao
    Chen, Tao
    Feng, Xiaobo
    MEDICINE, 2019, 98 (19)
  • [35] Neutrophil-lymphocyte ratio dynamics are useful for distinguishing between recurrence and pseudoprogression in high-grade gliomas
    Huang, Yong
    Ding, Haixia
    Wu, Qiuji
    Li, Zhiqiang
    Li, Huan
    Li, Sirui
    Xie, Conghua
    Zhong, Yahua
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6003 - 6009
  • [36] Factors affecting cognitive functions of patients with high-grade gliomas: a systematic review
    Tariq, Rabeet
    Hussain, Nowal
    Baqai, Muhammad Waqas Saeed
    NEUROLOGICAL SCIENCES, 2023, 44 (06) : 1917 - 1929
  • [37] Parametric Response Map As an Imaging Biomarker to Distinguish Progression From Pseudoprogression in High-Grade Glioma
    Tsien, Christina
    Galban, Craig J.
    Chenevert, Thomas L.
    Johnson, Timothy D.
    Hamstra, Daniel A.
    Sundgren, Pia C.
    Junck, Larry
    Meyer, Charles R.
    Rehemtulla, Alnawaz
    Lawrence, Theodore
    Ross, Brian D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) : 2293 - 2299
  • [38] Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis
    Sajeel A. Chowdhary
    Timothy Ryken
    Herbert B. Newton
    Journal of Neuro-Oncology, 2015, 122 : 367 - 382
  • [39] Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis
    Xu, Yanan
    Guan, Haijing
    Yu, Kefu
    Ji, Nan
    Zhao, Zhigang
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [40] Incidence and predictors of atrial fibrillation progression: A systematic review and meta-analysis
    Blum, Steffen
    Meyre, Pascal
    Aeschbacher, Stefanie
    Berger, Sebastian
    Auberson, Chloe
    Briel, Matthias
    Osswald, Stefan
    Conen, David
    HEART RHYTHM, 2019, 16 (04) : 502 - 510